146948-68-7

Usage

Uses

Used in Pharmaceutical Industry:
2-BROMO-4-CHLORO-6-METHYLANILINE is used as a chemical intermediate for the synthesis of various pharmaceuticals, contributing to the development of new medications and therapeutic agents.
Used in Dye Industry:
In the dye industry, 2-BROMO-4-CHLORO-6-METHYLANILINE is utilized as a precursor in the production of different types of dyes, enhancing the color spectrum and performance of these products.
Used in Agrochemical Industry:
2-BROMO-4-CHLORO-6-METHYLANILINE is employed as an intermediate in the synthesis of agrochemicals, playing a role in the development of pesticides and other agricultural chemicals to improve crop protection and yield.
Used in Organic Compounds Manufacturing:
2-BROMO-4-CHLORO-6-METHYLANILINE is used as a building block in the manufacturing of various organic compounds, contributing to the advancement of organic chemistry and the creation of new chemical entities with diverse applications.
Used in Organic Chemistry Research:
2-BROMO-4-CHLORO-6-METHYLANILINE serves as a valuable research tool in organic chemistry, aiding scientists in understanding the properties and reactions of substituted aniline derivatives, which can lead to the discovery of new chemical reactions and applications.

InChI:InChI=1/C7H7BrClN/c1-4-2-5(9)3-6(8)7(4)10/h2-3H,10H2,1H3

Upstream product

• 615-65-6 2-chloro-4-methyl-benzenamine 
• 329944-72-1 1-bromo-3-chloro-5-methylbenzene 
• 30273-42-8 2-methyl-4-bromo-6-chloroaniline 
• 24106-05-6 4'-bromo-2'-methylacetanilide 
• 7647-01-0 hydrogenchloride 
• 866998-75-6 3-bromo-5-chloro-2-nitro-toluene 
• 95-69-2 4-chloro-2-methylbenzeneamine 

Downstream Products

• 23813-33-4 N-(2-Bromo-4-chloro-6-methyl-phenyl)-N'-[1-nitro-eth-(Z)-ylidene]-hydrazine 
• 23813-58-3 N-(2-Bromo-4-chloro-6-methyl-phenyl)-N'-[1-nitro-prop-(Z)-ylidene]-hydrazine 
• 23750-67-6 1-(2-Bromo-4-chloro-6-methyl-phenyl)-3-(4-trifluoromethyl-phenyl)-urea 
• 500008-45-7 rynaxypyr 
• 1391132-23-2 2-hydroxyethyl 2-amino-5-chloro-3-methylbenzoate 
• 1391132-24-3 2-(dimethylamino)ethyl 2-amino-5-chloro-3-methylbenzoate 
• 890707-28-5 2-amino-3-methyl-5-chlorobenzoyl-N-methylamine 
• 939990-03-1 2-amino-5-chloro-3-methylbenzonitrile 
• 644961-69-3 4-chloro-2-methoxy-6-methylphenylamine 
• 84388-49-8 3-bromo-5-chloro-2,4,6-trinitro-toluene 

Relevant academic research and scientific papers

Fragment-Based Discovery of Novel Potent Sepiapterin Reductase Inhibitors

Genome-wide-association studies in chronic low back pain patients identified sepiapterin reductase as a high interest target for developing new analgesics. Here we used 19F NMR fragment screening for the discovery of novel, ligand-efficient SPR

ANTIBIOTIC COMPOUNDS

The present invention relates to antibiotic compounds of formula (I), to compositions containing these compounds and to methods of treating bacterial diseases and infections using the compounds. The compounds find application in the treatment of infection with, and diseases caused by, Gram-positive and/or Gram-negative bacteria, and in particular in the treatment of infection with, and diseases caused by, Neisseria gonorrhoeae.

Discovery of a 7-arylaminobenzimidazole series as novel CRF1receptor antagonists

A promising lead compound 1 of a benzimidazole series has been identified as a corticotropin-releasing factor 1 (CRF1) receptor antagonist. In this study, we focused on replacement of a 7-alkylamino group of 1, predicted to occupy a large lipophilic pocket of a CRF1receptor, with an aryl group. During the course of this examination, we established new synthetic approaches to 2,7-diarylaminobenzimidazoles. The novel synthesis of 7-arylaminobenzimidazoles culminated in the identification of compounds exhibiting inhibitory activities comparable to the alkyl analog 1. A representative compound, p-methoxyanilino analog 16g, showed potent CRF binding inhibitory activity against a human CRF1receptor and human CRF1receptor antagonistic activity (IC50?=?27?nM, 56?nM, respectively). This compound exhibited ex vivo125I-Tyr0(125I-CRF) binding inhibitory activity in mouse frontal cortex, olfactory bulb, and pituitary gland at 20?mg/kg after oral administration. In this report, we discuss the structure–activity-relationship of these 7-arylamino-1H-benzimidazoles and their synthetic method.

Substituted Heterocyclic Ethers and Their Use in CNS Disorders

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.

BENZIMIDAZOLE COMPOUNDS

There is provided a compound of the formula (1) wherein R1 is an optionally substituted C1-10 alkyl; R2 is H, or a C1-6 alkyl which may be substituted with 1 to 3 substituents; R3 is a 5- or 6-membered aromatic group which may be substituted with 1 to 5 substituents, wherein the 5- or 6-membered aromatic group may be fused with a 5- or 6- membered ring which may be substituted with 1 to 3 C1-6 alkyls; R4 is a hydrogen, a halogen, a hydroxy, a cyano, a C1-6 alkyl or a C1-6 alkoxy; Z is -O-, -S-, -SO-, -SO2-, or - NR5- wherein R5 is a hydrogen or a C1-6 alkyl; or a salt thereof or a prodrug thereof, which have CRF receptor antagonist activity and use thereof.